Hyperlipidemia - Pipeline Review, H1 2016

  • ID: 3641096
  • Drug Pipelines
  • 212 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acasti Pharma Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • BCWorld Pharm Co. Ltd.
  • Huons Co., Ltd.
  • Kowa Company, Ltd.
  • MORE
Hyperlipidemia - Pipeline Review, H1 2016

Summary

‘Hyperlipidemia - Pipeline Review, H1 2016’, provides an overview of the Hyperlipidemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperlipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperlipidemia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia
- The report reviews pipeline therapeutics for Hyperlipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hyperlipidemia therapeutics and enlists all their major and minor projects
- The report assesses Hyperlipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hyperlipidemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acasti Pharma Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • BCWorld Pharm Co. Ltd.
  • Huons Co., Ltd.
  • Kowa Company, Ltd.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Hyperlipidemia Overview

Therapeutics Development

Pipeline Products for Hyperlipidemia - Overview

Pipeline Products for Hyperlipidemia - Comparative Analysis

Hyperlipidemia - Therapeutics under Development by Companies

Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes

Hyperlipidemia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Hyperlipidemia - Products under Development by Companies

Hyperlipidemia - Products under Investigation by Universities/Institutes

Hyperlipidemia - Companies Involved in Therapeutics Development

Acasti Pharma Inc.

Allergan Plc

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Arbutus Biopharma Corporation

Arisaph Pharmaceuticals, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

BASF SE

BCWorld Pharm Co. Ltd.

Cadila Pharmaceuticals Ltd.

Cardax Pharmaceuticals, Inc.

Catabasis Pharmaceuticals, Inc.

CJ HealthCare Corp.

CymaBay Therapeutics, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Esperion Therapeutics, Inc.

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Huons Co., Ltd.

Hyundai Pharmaceutical Co., Ltd.

Innovent Biologics, Inc.

Jeil Pharmaceutical Co., Ltd.

Kowa Company, Ltd.

LG Life Science LTD.

Lotus Pharmaceutical Co., Ltd.

Pfizer Inc.

Pharmena SA

Prometheon Pharma, LLC

Protalix BioTherapeutics, Inc.

Sancilio & Company, Inc.

Thetis Pharmaceuticals LLC

Yuhan Corporation

Zydus Cadila Healthcare Limited

Hyperlipidemia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(amlodipine besylate + atorvastatin calcium + valsartan) - Drug Profile

(amlodipine besylate + rosuvastatin calcium + valsartan) - Drug Profile

(atorvastatin calcium + losartan potassium) - Drug Profile

(atorvastatin calcium + metformin hydrochloride) XR - Drug Profile

(candesartan + rosuvastatin calcium) - Drug Profile

(gemigliptin + rosuvastatin calcium) - Drug Profile

(metformin hydrochloride SR + rosuvastatin calcium) - Drug Profile

AEM-28 - Drug Profile

AEM-2802 - Drug Profile

AEM-2814 - Drug Profile

ALN-AC3 - Drug Profile

ALN-ANG - Drug Profile

ARI-3037MO - Drug Profile

AS-1708727 - Drug Profile

BCWPC-001 - Drug Profile

bempedoic acid - Drug Profile

bezafibrate ER - Drug Profile

BH-03004 - Drug Profile

BioE-1115 - Drug Profile

bococizumab - Drug Profile

BSN-272 - Drug Profile

CAT-2000 Series - Drug Profile

CAT-2003 - Drug Profile

CDX-085 - Drug Profile

centatin - Drug Profile

DS-8312 - Drug Profile

DWJ-1330 - Drug Profile

DWJ-1351 - Drug Profile

etanercept biosimilar - Drug Profile

evolocumab - Drug Profile

gemcabene calcium - Drug Profile

HOB-071 - Drug Profile

HU-012 - Drug Profile

IBI-306 - Drug Profile

icosabutate - Drug Profile

ISIS-APOCIIILRx - Drug Profile

JLP-1302 - Drug Profile

JLP-1401 - Drug Profile

K-312 - Drug Profile

leucine + niacin - Drug Profile

MAT-9001 - Drug Profile

MBX-8025 - Drug Profile

NKPL-66 - Drug Profile

Oligonucleotide for Hyperlipidemia and Atherosclerosis - Drug Profile

omega-3-carboxylic acids - Drug Profile

PF-06427878 - Drug Profile

PF-06815345 - Drug Profile

pitavastatin CR - Drug Profile

Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile

saroglitazar - Drug Profile

SC-401 - Drug Profile

Small Molecule for Hyperlipidemia - Drug Profile

Small Molecule for Hypertriglyceridaemia - Drug Profile

Small Molecule for Hypertriglyceridemia - Drug Profile

Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile

Small Molecule to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile

Small Molecules for Dyslipidemia and Hypertriglyceridemia - Drug Profile

Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile

TKM-HTG - Drug Profile

TKMApoC-3 - Drug Profile

TP-101 - Drug Profile

TRIA-662 - Drug Profile

volanesorsen sodium - Drug Profile

YH-22189 - Drug Profile

Hyperlipidemia - Recent Pipeline Updates

Hyperlipidemia - Dormant Projects

Hyperlipidemia - Dormant Projects

Hyperlipidemia - Discontinued Products

Hyperlipidemia - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hyperlipidemia, H1 2016

Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Hyperlipidemia - Pipeline by Acasti Pharma Inc., H1 2016

Hyperlipidemia - Pipeline by Allergan Plc, H1 2016

Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Hyperlipidemia - Pipeline by Amgen Inc., H1 2016

Hyperlipidemia - Pipeline by Arbutus Biopharma Corporation, H1 2016

Hyperlipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016

Hyperlipidemia - Pipeline by Astellas Pharma Inc., H1 2016

Hyperlipidemia - Pipeline by AstraZeneca Plc, H1 2016

Hyperlipidemia - Pipeline by BASF SE, H1 2016

Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016

Hyperlipidemia - Pipeline by Cadila Pharmaceuticals Ltd., H1 2016

Hyperlipidemia - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016

Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016

Hyperlipidemia - Pipeline by CJ HealthCare Corp., H1 2016

Hyperlipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016

Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016

Hyperlipidemia - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2016

Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2016

Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016

Hyperlipidemia - Pipeline by Huons Co., Ltd., H1 2016

Hyperlipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016

Hyperlipidemia - Pipeline by Innovent Biologics, Inc., H1 2016

Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016

Hyperlipidemia - Pipeline by Kowa Company, Ltd., H1 2016

Hyperlipidemia - Pipeline by LG Life Science LTD., H1 2016

Hyperlipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H1 2016

Hyperlipidemia - Pipeline by Pfizer Inc., H1 2016

Hyperlipidemia - Pipeline by Pharmena SA, H1 2016

Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H1 2016

Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2016

Hyperlipidemia - Pipeline by Sancilio & Company, Inc., H1 2016

Hyperlipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016

Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2016

Hyperlipidemia - Pipeline by Zydus Cadila Healthcare Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2016

Hyperlipidemia - Dormant Projects, H1 2016

Hyperlipidemia - Dormant Projects (Contd..1), H1 2016

Hyperlipidemia - Dormant Projects (Contd..2), H1 2016

Hyperlipidemia - Dormant Projects (Contd..3), H1 2016

Hyperlipidemia - Dormant Projects (Contd..4), H1 2016

Hyperlipidemia - Dormant Projects (Contd..5), H1 2016

Hyperlipidemia - Dormant Projects (Contd..6), H1 2016

Hyperlipidemia - Dormant Projects (Contd..7), H1 2016

Hyperlipidemia - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Hyperlipidemia, H1 2016

Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Acasti Pharma Inc.
Allergan Plc
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Arbutus Biopharma Corporation
Arisaph Pharmaceuticals, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
BASF SE
BCWorld Pharm Co. Ltd.
Cadila Pharmaceuticals Ltd.
Cardax Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
CJ HealthCare Corp.
CymaBay Therapeutics, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Esperion Therapeutics, Inc.
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Huons Co., Ltd.
Hyundai Pharmaceutical Co., Ltd.
Innovent Biologics, Inc.
Jeil Pharmaceutical Co., Ltd.
Kowa Company, Ltd.
LG Life Science LTD.
Lotus Pharmaceutical Co., Ltd.
Pfizer Inc.
Pharmena SA
Prometheon Pharma, LLC
Protalix BioTherapeutics, Inc.
Sancilio & Company, Inc.
Thetis Pharmaceuticals LLC
Yuhan Corporation
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll